Skip to main content

Table 3 Tumor response by treatment free-interval in patients treated as second-line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Tumor Response Treatment free-interval (N = 20)
  < 3 months 3-6 months > 6 months
  No. (%) No. (%) No. (%)
Complete response 1 (7.7) 0 (0) 0 (0)
Partial response 5 (38.5) 1 (33) 3 (75)
Stable disease 2 (15.4) 2 (67) 1 (25)
Progressive disease 5 (38.5) 0 (0) 0 (0)
Total 13 (100) 3 (100) 4 (100)